JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB32071

Anti-PARP1 antibody [E78]

  • RabMAb
  • Recombinant
  • KO Validated
  • Lab Essentials
  • 20ul selling size
  • What is this?

5

(2 Reviews)

|

(32 Publications)

Rabbit Recombinant Monoclonal PARP1 antibody. Suitable for WB and reacts with Human samples. Cited in 32 publications.

View Alternative Names

ADPRT, PPOL, PARP1, Poly [ADP-ribose] polymerase 1, PARP-1, ADP-ribosyltransferase diphtheria toxin-like 1, DNA ADP-ribosyltransferase PARP1, NAD(+) ADP-ribosyltransferase 1, Poly[ADP-ribose] synthase 1, Protein poly-ADP-ribosyltransferase PARP1, ARTD1, ADPRT 1

3 Images
Western blot - Anti-PARP1 antibody [E78] (AB32071)
  • WB

Unknown

Western blot - Anti-PARP1 antibody [E78] (AB32071)

pro-form : 116kDa; p85 caspases cleaved form : 85kDa; proteolysis cleaved fragments : 71kDa, 55kDa and 42kDa

All lanes:

Western blot - Anti-PARP1 antibody [E78] (ab32071) at 1/1000 dilution

Lane 1:

Untreated Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate at 20 µg

Lane 2:

Jurkat (Human T cell leukemia T lymphocyte) treated with 1μM staurosporine for 4 hours whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 113 kDa

false

Western blot - Anti-PARP1 antibody [E78] (AB32071)
  • WB

Lab

Western blot - Anti-PARP1 antibody [E78] (AB32071)

Lane 1 : Wild type HAP1 whole cell lysate (20 μg)
Lane 2 : PARP1 knockout HAP1 whole cell lysate (20 μg)
Lane 3 : HeLa whole cell lysate (20 μg)
Lane 4 : MCF7 whole cell lysate (20 μg)

Lanes 1 - 4 : Merged signal (red and green). Green ab32071 observed at 125 kDa. Red - loading control, ab8245, observed at 37 kDa.

ab32071 was shown to specifically react with PARP1 when PARP1 knockout samples were used. Wild-type and PARP1 knockout samples were subjected to SDS-PAGE. ab32071 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10 000 dilution respectively. Blots were developed with 800CW Goat anti Rabbit and 680CW Goat anti Mouse secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-PARP1 antibody [E78] (ab32071)

Predicted band size: 113 kDa

false

Western blot - Anti-PARP1 antibody [E78] (AB32071)
  • WB

CiteAb

Western blot - Anti-PARP1 antibody [E78] (AB32071)

PARP1 western blot using anti-PARP1 antibody [E78] ab32071. Publication image and figure legend from Lassalle, S., Zangari, J., et al., 2016, Oncotarget, PubMed 27036030.

ab32071 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab32071 please see the product overview.

Effect of miR-375 on proliferation and cancer drug responseA. Nthy-ori 3-1 cells were seeded and transfected with pre-miR-375 or pre-miR-CTL at 20pM for 24h and vandetanib was then added for 48h. Dead cells were stained with propidium iodide (red) before microscopic analysis. Pictures representative of four biological replicates. B. Quantification of propidium iodide positive Nthy-ori 3-1 cells. C. Nthy-ori 3-1 cells were seeded and transfected with pre-miR-375 or pre-miR-CTL at 20pM for 24h and vandetanib was then added for 48h. Quantification of ERK, AKT pathways and PARP cleavage was performed by immunoblot. Tubulin (TUBA) and actin B (ACTB) protein levels were used as loading controls. D. Nthy-ori 3-1 cells were seeded in 96-well plates and transfected with pre-miR-375 or pre-miR-CTL either at 6.25, 12.5, 25 pM for 24h and then treated with either 1.25, 2.5, 5μM vandetanib for 48h. Cell proliferation was evaluated using BrdU incorporation for 3h. Single doses and combination doses were analysed using Compusyn software and a Combination index/effect dot plot was generated. CI<1 values are indicative of synergism. E. TT cells were seeded and transfected with antagomiR-375 (anti-miR-375) or antagomiR-CTL (anti-miR-CTL) for 24h and vandetanib was then added for 48h. Quantification of propidium iodide positive TT cells.

false

  • Carrier free

    Anti-PARP1 antibody [E78] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

E78

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

ab32071 should recognise both pro-form and p85 cleaved-form of PARP1.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" } } }

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PARP1 also known as poly(ADP-ribose) polymerase 1 is an enzyme that plays an important role in DNA repair processes. It detects DNA single-strand breaks and uses NAD+ as a substrate to add ADP-ribose polymers to itself and other proteins. This post-translational modification signals DNA repair machinery to the site of damage. PARP1 has a molecular weight of approximately 116 kDa. It is widely expressed in the nucleus of eukaryotic cells. PARP1 is often studied by western blotting techniques to analyze its expression and activation levels.
Biological function summary

Poly(ADP-ribose) polymerase 1 functions to maintain genomic stability by acting within the base excision repair complex. This complex is important for the detection and repair of DNA damage preventing the accumulation of mutations. By acting at sites of DNA stress PARP1 facilitates the binding of DNA repair proteins stabilizing the DNA structure during the repair process. This role is significant for cells that undergo frequent DNA replication or are exposed to high levels of genotoxic stress.

Pathways

The PARP1 protein is integral to the DNA damage response and repair pathway. It interacts with other proteins such as XRCC1 to coordinate repair activities at damaged DNA sites. Another important pathway involving PARP1 is the apoptosis pathway where excessive activation of PARP1 can lead to cell death due to depletion of cellular NAD+ and ATP. This indicates its dual role in both promoting cell survival through DNA repair and contributing to cell death when damage is irreparable.

Poly(ADP-ribose) polymerase 1 is strongly linked to cancer and neurodegenerative diseases. Its activity is heightened in many cancer types where cancer cells exploit PARP1 for survival by repairing DNA damage that would otherwise be lethal. Inhibitors of PARP1 are being developed as cancer therapies to target these survival mechanisms. Moreover overactivation of PARP1 in neurodegenerative disorders like Alzheimer's disease can lead to excessive energy consumption promoting neuronal cell damage. In these contexts PARP1 connects with proteins like BRCA1 in cancer or AIF in neurodegeneration illustrating its role in disease mechanisms.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair (PubMed : 17177976, PubMed : 18055453, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 20388712, PubMed : 21680843, PubMed : 22582261, PubMed : 23230272, PubMed : 25043379, PubMed : 26344098, PubMed : 26626479, PubMed : 26626480, PubMed : 30104678, PubMed : 31796734, PubMed : 32028527, PubMed : 32241924, PubMed : 32358582, PubMed : 33186521, PubMed : 34465625, PubMed : 34737271). Mediates glutamate, aspartate, serine, histidine or tyrosine ADP-ribosylation of proteins : the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units (PubMed : 19764761, PubMed : 25043379, PubMed : 28190768, PubMed : 29954836, PubMed : 35393539, PubMed : 7852410, PubMed : 9315851). Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage (PubMed : 33186521, PubMed : 34874266). Specificity for the different amino acids is conferred by interacting factors, such as HPF1 and NMNAT1 (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 confers serine specificity by completing the PARP1 active site (PubMed : 28190768, PubMed : 29954836, PubMed : 32028527, PubMed : 33186521, PubMed : 33589610, PubMed : 34625544, PubMed : 34874266). Also catalyzes tyrosine ADP-ribosylation of target proteins following interaction with HPF1 (PubMed : 29954836, PubMed : 30257210). Following interaction with NMNAT1, catalyzes glutamate and aspartate ADP-ribosylation of target proteins; NMNAT1 confers glutamate and aspartate specificity (By similarity). PARP1 initiates the repair of DNA breaks : recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones (H2BS6ADPr and H3S10ADPr), thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks (PubMed : 17177976, PubMed : 18172500, PubMed : 19344625, PubMed : 19661379, PubMed : 23230272, PubMed : 27067600, PubMed : 34465625, PubMed : 34874266). HPF1 initiates serine ADP-ribosylation but restricts the polymerase activity of PARP1 in order to limit the length of poly-ADP-ribose chains (PubMed : 33683197, PubMed : 34732825, PubMed : 34795260). In addition to base excision repair (BER) pathway, also involved in double-strand breaks (DSBs) repair : together with TIMELESS, accumulates at DNA damage sites and promotes homologous recombination repair by mediating poly-ADP-ribosylation (PubMed : 26344098, PubMed : 30356214). Mediates the poly-ADP-ribosylation of a number of proteins, including itself, APLF, CHFR, RPA1 and NFAT5 (PubMed : 17396150, PubMed : 19764761, PubMed : 24906880, PubMed : 34049076). In addition to proteins, also able to ADP-ribosylate DNA : catalyzes ADP-ribosylation of DNA strand break termini containing terminal phosphates and a 2'-OH group in single- and double-stranded DNA, respectively (PubMed : 27471034). Required for PARP9 and DTX3L recruitment to DNA damage sites (PubMed : 23230272). PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites (PubMed : 23230272). PARP1-mediated DNA repair in neurons plays a role in sleep : senses DNA damage in neurons and promotes sleep, facilitating efficient DNA repair (By similarity). In addition to DNA repair, also involved in other processes, such as transcription regulation, programmed cell death, membrane repair, adipogenesis and innate immunity (PubMed : 15607977, PubMed : 17177976, PubMed : 19344625, PubMed : 27256882, PubMed : 32315358, PubMed : 32844745, PubMed : 35124853, PubMed : 35393539, PubMed : 35460603). Acts as a repressor of transcription : binds to nucleosomes and modulates chromatin structure in a manner similar to histone H1, thereby altering RNA polymerase II (PubMed : 15607977, PubMed : 22464733). Acts both as a positive and negative regulator of transcription elongation, depending on the context (PubMed : 27256882, PubMed : 35393539). Acts as a positive regulator of transcription elongation by mediating poly-ADP-ribosylation of NELFE, preventing RNA-binding activity of NELFE and relieving transcription pausing (PubMed : 27256882). Acts as a negative regulator of transcription elongation in response to DNA damage by catalyzing poly-ADP-ribosylation of CCNT1, disrupting the phase separation activity of CCNT1 and subsequent activation of CDK9 (PubMed : 35393539). Involved in replication fork progression following interaction with CARM1 : mediates poly-ADP-ribosylation at replication forks, slowing fork progression (PubMed : 33412112). Poly-ADP-ribose chains generated by PARP1 also play a role in poly-ADP-ribose-dependent cell death, a process named parthanatos (By similarity). Also acts as a negative regulator of the cGAS-STING pathway (PubMed : 32315358, PubMed : 32844745, PubMed : 35460603). Acts by mediating poly-ADP-ribosylation of CGAS : PARP1 translocates into the cytosol following phosphorylation by PRKDC and catalyzes poly-ADP-ribosylation and inactivation of CGAS (PubMed : 35460603). Acts as a negative regulator of adipogenesis : catalyzes poly-ADP-ribosylation of histone H2B on 'Glu-35' (H2BE35ADPr) following interaction with NMNAT1, inhibiting phosphorylation of H2B at 'Ser-36' (H2BS36ph), thereby blocking expression of pro-adipogenetic genes (By similarity). Involved in the synthesis of ATP in the nucleus, together with NMNAT1, PARG and NUDT5 (PubMed : 27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed : 27257257).. Poly [ADP-ribose] polymerase 1, processed C-terminus. Promotes AIFM1-mediated apoptosis (PubMed : 33168626). This form, which translocates into the cytoplasm following cleavage by caspase-3 (CASP3) and caspase-7 (CASP7) in response to apoptosis, is auto-poly-ADP-ribosylated and serves as a poly-ADP-ribose carrier to induce AIFM1-mediated apoptosis (PubMed : 33168626).. Poly [ADP-ribose] polymerase 1, processed N-terminus. This cleavage form irreversibly binds to DNA breaks and interferes with DNA repair, promoting DNA damage-induced apoptosis.
See full target information PARP1

Publications (32)

Recent publications for all applications. Explore the full list and refine your search

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 57:633-643 PubMed40754897

2025

[Multi-omics analysis of the relationship between oxidative stress-related gene and prostate cancer].

Applications

Unspecified application

Species

Unspecified reactive species

J Ning,H Wang,S Luo,J Jing,J Wang,H Hou,M Liu

Cancer research communications 4:2427-2443 PubMed39028932

2024

Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation.

Applications

Unspecified application

Species

Unspecified reactive species

Anna Rutkowska,H Christian Eberl,Thilo Werner,Marco L Hennrich,Daniel C Sévin,Massimo Petretich,James P Reddington,Shirin Pocha,Stephan Gade,Amalia Martinez-Segura,Dmytro Dvornikov,Joel Karpiak,Gavain M A Sweetman,Christian Fufezan,Birgit Duempelfeld,Florian Braun,Christopher Schofield,Hakan Keles,David Alvarado,Zhuo Wang,Keith H Jansson,Maria Faelth-Savitski,Edward Curry,Katja Remlinger,Euan A Stronach,Bin Feng,Geeta Sharma,Kevin Coleman,Paola Grandi,Marcus Bantscheff,Giovanna Bergamini

Cell death & disease 15:48 PubMed38218922

2024

Akt enhances the vulnerability of cancer cells to VCP/p97 inhibition-mediated paraptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Dong Min Lee,In Young Kim,Hong Jae Lee,Min Ji Seo,Mi-Young Cho,Hae In Lee,Gyesoon Yoon,Jae-Hoon Ji,Seok Soon Park,Seong-Yun Jeong,Eun Kyung Choi,Yong Hyeon Choi,Chae-Ok Yun,Mirae Yeo,Eunhee Kim,Kyeong Sook Choi

Cancer science 114:3583-3594 PubMed37650703

2023

Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Seok Soon Park,Mi Ri Kwon,Eun Jin Ju,Seol Hwa Shin,Jin Park,Eun Jung Ko,Ga Won Son,Hye Won Lee,Yeon Joo Kim,Gyeong Joon Moon,Yun-Yong Park,Si Yeol Song,Seong-Yun Jeong,Eun Kyung Choi

Cancer cell international 23:172 PubMed37596639

2023

ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.

Applications

Unspecified application

Species

Unspecified reactive species

Seol Hwa Shin,Eun Jin Ju,Jin Park,Eun Jung Ko,Mi Ri Kwon,Hye Won Lee,Ga Won Son,Yun-Yong Park,Yeon Joo Kim,Si Yeol Song,Sangkwang Lee,Beom Seok Seo,Jin-A Song,Sangbin Lim,Doohwan Jung,Sunyoung Kim,Hyangsook Lee,Seok Soon Park,Seong-Yun Jeong,Eun Kyung Choi

Frontiers in oncology 12:824043 PubMed35494068

2022

Z-Ligustilide Induces c-Myc-Dependent Apoptosis Activation of ER-Stress Signaling in Hypoxic Oral Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Ren-Jun Hsu,Kui-Yuan Peng,Wen-Lin Hsu,Yu-Tang Chen,Dai-Wei Liu

Oncology letters 22:852 PubMed34733370

2021

Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK/AKT/mTOR signaling pathway .

Applications

Unspecified application

Species

Unspecified reactive species

Yuying Fan,Xiaoli Ren,Yingxue Wang,Enshuang Xu,Shuang Wang,Ruidong Ge,Yun Liu

Nanomaterials (Basel, Switzerland) 11: PubMed34443774

2021

Titanium Dioxide Induces Apoptosis under UVA Irradiation via the Generation of Lysosomal Membrane Permeabilization-Dependent Reactive Oxygen Species in HaCat Cells.

Applications

Unspecified application

Species

Unspecified reactive species

In Young Kim,Tae Geol Lee,Vytas Reipa,Min Beom Heo

International journal of molecular sciences 22: PubMed34073232

2021

Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Marina Pisano,Maria Antonietta Dettori,Davide Fabbri,Giovanna Delogu,Giuseppe Palmieri,Carla Rozzo

PloS one 16:e0249059 PubMed33793628

2021

Cell competition between anaplastic thyroid cancer and normal thyroid follicular cells exerts reciprocal stress response defining tumor suppressive effects of normal epithelial tissue.

Applications

Unspecified application

Species

Unspecified reactive species

Aidana Amrenova,Keiji Suzuki,Vladimir Saenko,Shunichi Yamashita,Norisato Mitsutake
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com